Vericel Corp

VCEL is the ticker symbol for Vericel Corp, a publicly traded US company.

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Key metrics include a return on equity of -1.8%, a debt-to-equity ratio of 0.36.

The company reports trailing twelve-month revenue of $68.42M and net loss of $6.30M.

FINOTAUR aggregates real-time and fundamental data on VCEL to help traders and investors make informed decisions. Track VCEL in your trading journal alongside other positions for a unified view of your portfolio.